|Table of Contents|

Exosome hsa-miR-522-3p is involved in ovarian cancer progression by regulating CDK6

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4334-4340
Research Field:
Publishing date:

Info

Title:
Exosome hsa-miR-522-3p is involved in ovarian cancer progression by regulating CDK6
Author(s):
LI Ya; ZHANG Fang
Department of Gynecology，Hengyang Central Hospital,Hunan Hengyang 421000,China.
Keywords:
ovarian cancer; exosome; hsa-miR-522-3p; CDK6
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.23.007
Abstract:
Objective:To explore the role of exosome hsa-miR-522-3p in the occurrence and development of ovarian cancer and its potential mechanism.Methods:Real time quantitative PCR was used to detect the expression level of hsa-miR-522-3p in tissues and cells.The effects of extracellular vesicles and hsa-miR-522-3p on cell proliferation,migration,invasion,and apoptosis were detected using EdU,Transwell,and flow cytometry.Evaluate the regulatory effect of hsa-miR-522-3p on CDK6 expression through luciferase assay and Western blotting.Further construct a nude mouse tumor formation model to verify the effect of exosomes hsa-miR-522-3p on tumor growth.Results:This study found that hsa-miR-522-3p was significantly increased in ovarian cancer tissue,plasma exosomes,and exosomes of ovarian cancer cells.Compared with the NC group,the migration and invasion ability of cells in the hsa-miR-522-3p group was significantly increased,and the differences were statistically significant(P＜0.05).In addition,the hsa-miR-522-3p inhibition group can promote the expression of caspase3 and Bax and inhibit the expression of Bcl2.The results of double luciferase report showed that hsa-miR-522-3p could target the 3'-untranslated region(3'-UTR) of CDK6 to inhibit its expression.The results of tumor formation in nude mice indicate that the exosomes hsa-miR-522-3p can increase the volume and weight of the tumor.Conclusion:Exosomes hsa-miR-522-3p participate in the progression of ovarian cancer by regulating CDK6.The findings of this study will provide new insights into the mechanism of exosomes hsa-miR-522-3p in the development of ovarian cancer.

References:

［1］DING T,TANG D,XI MR.The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer:A systematic review and Meta-analysis［J］.Journal of Ovarian Research,2021,14(1):93.
［2］KRASNIQI E,SACCONI A,MARINELLI D,et al.MicroRNA-based signatures impacting clinical course and biology of ovarian cancer:A miRNOmics study［J］.Biomarker Research,2021,9(1):57.
［3］DIOUN SHAYAN,WU JENNEY,CHEN L,et al.Intraoperative rupture of the ovarian capsule in early-stage ovarian cancer:A Meta-analysis［J］.Obstetrics & Gynecology,2021,138(2):261-271.
［4］YAN X,ZHANG SY,JIA JM,et al.Exploring the malnutrition status and impact of total parenteral nutrition on the outcome of patients with advanced stage ovarian cancer［J］.BMC Cancer,2021,21(1):799.
［5］WANG S,WANG CX,LIU OX,et al.miRNA-651-3p regulates EMT in ovarian cancer cells by targeting ZNF703 and via the MEK/ERK pathway［J］.Biochemical and Biophysical Research Communications,2022,619(1):76-83.
［6］ZHAO LH,LIANG XL,WANG LY,et al.The role of miRNA in ovarian cancer:An overview［J］.Reproductive Sciences,2022,29(10):2760-2767.
［7］NOZOMI HOJO,ALYSE HILL,EVGENY CHIRSHEV,et al.Mechanism of tumor suppressor miRNA let-7 downregulation in ovarian cancer:Transcription factor Snail represses let-7 and is associated with invasiveness phenotype［J］.Gynecologic Oncology,2017,147(1):243-252.
［8］戴文砚,王可可,王金华.外泌体microRNAs在卵巢癌诊断和治疗中作用的研究进展［J］.肿瘤学杂志,2023,29(1):19-23. DAI WY,WANG KK,WANG JH.Research progress on the role of exosomal microRNAs in the diagnosis and treatment of ovarian cancer［J］.Journal of Oncology,2023,29(1):19-23.
［9］程琳，李凤，许天敏.外泌体在卵巢癌诊疗中的研究进展［J］.现代肿瘤医学，2017,25（14）：2343-2346. CHENG L,LI F,XU TM.The biological significance and clinical applications of exosomes in ovarian cancer［J］.Modern Oncology，2017,25（14）：2343-2346.
［10］张红梅,梁艳丽,席源,等.miR-205-5p在卵巢癌患者血清中的表达及其预后价值［J］.中南医学科学杂志,2022,50(2):257-260. ZHANG HM,LIANG YL,XI Y,et al.Expression and prognostic value of miR-205-5p in serum of ovarian cancer patients［J］.Medical Science Journal of Central South China,2022,50(2):257-260.
［11］叶大文,关翰,毛溧凯,等.miR-522-3p通过靶向调节SMAD2促进前列腺癌恶性进展［J］.齐齐哈尔医学院学报,2022,43(9):801-806. YE DW,GUAN H,MAO LK,et al.miR-522-3p promotes malignant progression of prostate cancer through targeted regulation of SMAD2［J］.Journal of Qiqihar Medical College,2022,43(9):801-806.
［12］易婧妍.CDK4/6抑制剂Palbociclib与PARP抑制剂Olaparib联合治疗卵巢癌的有效性及分子机制研究［D］.大连：大连医科大学,2020. YI JY.Efficacy and molecular mechanism of CDK4/6 inhibitor Palbociclib combined with PARP inhibitor Olaparib in the treatment of ovarian cancer［D］.Dalian：Dalian Medical College,2020.
［13］沈树娜,王辉,宫本丽.miRNA29靶基因CCND2和CDK6在宫颈癌中的表达研究［J］.中国妇幼健康研究,2018,29(1):56-58. SHEN SN,WANG H,GONG BL.Expression of miRNA29 target genes CCND2 and CDK6 in cervical cancer［J］.Chinese Journal of Women and Child Health Reaserch,2018,29(1):56-58.
［14］陈佞玄,罗鑫,易萍,等.卵巢癌的表观遗传学调控机制及其应用进展［J］.中国优生与遗传杂志,2023,31(1):1-7. CHEN LX,LUO X,YI P,et al.Epigenetic regulation mechanism of ovarian cancer and its application progress［J］.Chinese Journal of Bright Health & Heredity,2023,31(1):1-7.
［15］GYEOUNG-JIN KANG,HYE-JA LEE,HYUN JUNG BYUN,et al.Novel involvement of miR-522-3p in high-mobility group box 1-induced prostaglandin reductase 1 expression and reduction of phagocytosis［J］.BBA-Molecular Cell Research,2017,1864(4):625-633.
［16］SHUAI F,WANG B,DONG SX.miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein［J］.Oncology Research,2018,26(7):1113-1121.
［17］凌晨,刘蜀,王勇,等.CDK6在早期卵巢癌中表达及其临床意义［J］.南方医科大学学报,2016,36(9):1271-1275. LING C,LIU S,WANG Y,et al.Expression and clinical significance of CDK6 in early ovarian cancer［J］.Journal of Southern Medical University,2016,36(9):1271-1275.
［18］李阳.基于高通量技术的HPV相关全基因组分析及特定miRNA在宫颈癌发生中的作用与机制［D］.杭州：浙江大学,2012. LI Y.The role and mechanism of HPV-associated Genome-Wide analysis based on high throughput techniques and specific miRNA in cervical carcinogenesis［D］.Hangzhou:Zhejiang University,2012.
［19］艾中伟.CDK6蛋白在子宫颈癌患者中的表达及其临床意义［D］.长春：吉林大学,2019. AI ZW.Expression and clinical significance of CDK6 protein in cervical cancer patients［D］.Changchun:Jilin University,2019.
［20］王辉,沈树娜,王俊飞.宫颈癌组织中CDK6的表达及临床意义［J］.中国现代医学杂志,2022,23(34):60-62. WANG H,SHEN SN,WANG JF.Expression and clinical significance of CDK6 in cervical cancer［J］.China Journal of Modern Medicine,2022,23(34):60-62.

Memo

Memo:
湖南省衡阳市指导性计划项目(编号：202222035651)
Last Update: 2023-10-31